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processes and decisions. The health economics and health policy
literature was reviewed for commentaries and case studies of par-
ticular decisions. Where decisions had been made by different
bodies on the same technology those were reviewed for consis-
tency. Parallels were drawn with methods of regulating market
access in other European countries. RESULTS: NICE procedures
were the most thorough but could not be applied early or to all
technologies because of their resource- intensive nature. Method-
ological expectations for company submissions were similar
between organisations, but the degree of independent review
varied with the annual number of technologies assessed. In 
most cases, NICE and SMC decisions on the same drug were
consistent. SMC most resembled equivalent systems in other
European countries by evaluating drugs at launch. AWMSG was
most concerned with budget impact. CONCLUSIONS: Most dif-
ferences between the organisations could be explained by their
differing objectives, scope of activities and timing of their inter-
vention. The SMC was more concerned with timely and com-
prehensive coverage of all drugs, reﬂecting its closer links to
NHS. NICE was only beginning to address implementation.
Properly co-coordinated, the sequence of evaluations could
follow a logical development of evidence quality over time, with
minimal redundant work on company submissions. Without
such co-ordination a waste of valuable time and resources is
likely.
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OBJECTIVE: The Medicare Prescription Drug, Improvement
and Modernization Act (MMA) of 2003 directed the Medicare
Payment Advisory Commission (MedPAC) to conduct a study of
hospital pharmacy handling costs. The June 2005 MedPAC
report recommended payment for handling costs of Part B spec-
iﬁed outpatient drugs based on submitted charges, reduced to
costs. This study explores policy implications of MedPAC rec-
ommendations concerning potential OPPS pharmacy handling
cost payment methodology. METHODS: Various methods of
recording charges for pharmacy services were collected from a
hospital survey of systems (n = 399) and categorized. Past CMS
and MedPAC discussions of pharmacy costs and charges were
identiﬁed and accumulated in an indexed database. Findings
from the hospital sources and the governmental sources were
compared and underlying assumptions examined with a view
toward predicting 2006 CMS approaches to determining hospi-
tal pharmacy handling cost payment. RESULTS: The hospital
survey revealed signiﬁcant variation in whether hospital phar-
macy department drug charges recognize overhead such as han-
dling costs. Forty-three percent of survey respondents did include
such a charge. Types of charges reported were for dispensing
(35%), compounding (25%), a combination of dispensing and
compounding (23%) and all other (17%). When entries in the
indexed database of CMS and MedPAC discussions of pharmacy
costs and charges were compared to the hospital responses about
actual departmental cost and charge methods currently in use,
analyses revealed a signiﬁcant differential between methods
reported by hospital respondents (including charge compression)
and methods discussed in published CMS and MedPAC sources.
CONCLUSIONS: Future payment rates for hospital pharmacy
handling costs will likely be derived from hospital submitted
charges, per the MedPAC recommendation. If the payment
methodology does not take existing variations of recording phar-
macy costs and charges into account, the resulting method will
be signiﬁcantly ﬂawed and hospital providers may ﬁnd they are
underpaid for pharmacy handling costs in 2006.
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OBJECTIVES: The Spanish Agency of Medicines and Health
care Products (SAMHP) makes regulatory decisions concerning
pharmacovigilance. Here, we analyse the impact of actions
related to safety adopted by the SAMHP on drug consumption
ﬁnanced by the Spanish National Health System (NHS), over the
period 1990–2004. METHODS: A retrospective analysis of the
consumption was made, selecting drugs which were eventually
withdrawn from the market. Consumption data was provided
by the Ministry of Health and Consume (MHC) database and
expressed as number of prescriptions. Drugs selected were 
classiﬁed according to type of Adverse Drug Reaction (ADR),
Anatomic Therapeutic-Chemical Classiﬁcation (ATC) and degree
of therapeutic innovation at the moment of authorisation,
according to the MHC. RESULTS: Fourteen drugs were selected
for the purpose of this study, and none of these were categorised
as “an exceptional therapeutic novelty”. The most common
ADRs concerned severe liver (7/14) or heart (5/7) toxicity. At
least 8 of the 14 drugs were associated with one safety action
before being withdrawn. This was either a product labeling 
modiﬁcation (astemizole, droxicam, nimesulide, nefazodone,
cerivastatine, trovaﬂoxacine, and rofecoxib) or classiﬁcation as
hospitalary diagnostic (cisapride). Rofecoxib was the only one
with two actions. A high level of consumption and in a very short
time from authorisation until the ﬁrst safety action (between one
to three years) was found in nimesulide, cerivastatine and rofe-
coxib. In the rest of the drugs, the only action was the with-
drawn. This happened after one year post-authorisation
(tolcapone, sertindol, and grepaﬂoxacine) or in the case of ebro-
tidine, two years. CONCLUSIONS: The drugs withdrawn after
one or two years from their authorisation would seem reason-
able not have been ﬁnanced by NHS. In all drugs, the ﬁrst safety
action resulted in a signiﬁcant decrease in consumption. In some
of these cases, manufacturers requested to SAMHP drug to be
withdrawn.
PHP16
ESTIMATING THE COST SAVINGS AND RATIONAL USE
EFFECTS OF IMPLEMENTING AN ESSENTIAL MEDICINES LIST
Hamidi S1, Khan M1, Babo D1, Culbertson R1, Rice J1,Younis M2
1Tulane University, New Orleans, LA, USA; 2Jackson State University,
Jackson, MS, USA
OBJECTIVES: To determine the effects of implementing essen-
tial medicines list on rational use of medicines and medicine cost
savings in the public sector of West Bank, Palestine. METHODS:
The effect of EML on medicine expenditure was divided into two
separate components: the effect of EML on quantities used, and
the effect on medicine prices. The quantities of 76 medicine
groups were used as the dependent variable with real GDP per
capita, EML dummy, hospital dummy, time, and percent of
insured population, as independent variables. Another set of
regressions were deﬁned with real medicine price per deﬁned
daily dose as dependent variable and real GDP per capita, EML,
and percent insured as independent variables. A sample of pre-
scriptions was also analyzed to measure the indices of rational
medicine use. The indicators of rational use of medicines were
assumed to be a function of EML, and 16 health center dummy
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variables. RESULTS: Expenditures on medicines declined due to
negative impact of EML on quantities of medicines utilized per
capita as well as on real prices. The quantities declined on
average by 1.7 DDDs per capita per year. The medicine price
reduced on average by about US $0.0013 per deﬁned daily dose.
The real cost saved for the years 2000 to 2003 was about US $
5.9 million. The EML was effective in shifting all prescribing
indicators towards the standard values. CONCLUSIONS: The
PMOH should allocate more resources for pharmaceutical
budget in the future. The EML was successful in containing med-
icine cost, and careful review and update of EML should further
increase the savings. The development and implementation of
antibiotic medicine policy is an urgent need. Introduction of
treatment protocols for the most common diseases, and con-
tinuous education on rational medicine use for medical staff 
is required.
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OBJECTIVE: Mandatory generic substitution of prescribed
drugs aiming to moderate the cost increase of pharmaceuticals
within the pharmaceutical beneﬁts scheme, PBS, was introduced
in October 2002. The study aims to investigate if the introduc-
tion of generic substitution had an impact on the development
of drugs costs in Sweden for prescribed drugs within PBS and in
total. METHODS: Data on the sales of pharmaceuticals to each
county council and to the country in total was obtained. Data
comprised both total sales (prescriptions, hospitals sales and over
the counter sales) and sales of prescribed drugs within the PBS
was used for the period January 2000 to May 2005. Expendi-
ture data was expressed as retail prices excluding VAT per 1000
inhabitants in Swedish krona (SEK). Interrupted time series
analysis was used to investigate effects related to generic substi-
tution. RESULTS: The county councils’ total cost for pharma-
ceuticals increased from 230 SEK/inhabitants in January 2000 to
280 SEK/inhabitant in May 2005. The county councils’ average
monthly costs for PBS pharmaceuticals lay in three segments one
had a constant cost of ~40 SEK/inhabitant over the study period,
the second segment increased from ~140 SEK/inhabitant in 2000
to ~170 SEK/inhabitant in late 2002 where it stabilized and the
third segment ~190 SEK/inhabitant in 2000 and increased to
~210 SEK/inhabitants in late 2002 and after that it was constant.
Generic substitution was associated with reduced the slope of
increase of costs for drugs within the PBS for the whole country
and several of the county councils according to preliminary
analyses. This was also seen for several of the county councils’
total costs immediately after the introduction of generic substi-
tution. CONCLUSIONS: Preliminary analyses show that generic
substitution had an impact in the pace of increase of pharma-
ceutical expenditures.
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OBJECTIVES: The aim of this study is to analyse the small are
inequalities in the health insurance reimbursement of drugs in
Hungary. METHODS: Data derives from the central database
of the Hungarian National Health Insurance Fund Administra-
tion (OEP) covering the year 2003 and containing all the drug
reimbursement information from the whole country. For the
analysis we used three different kinds of drug expenditures
according to the source of funding: health insurance reimburse-
ment (paid by OEP), maximum reimbursement for socially hand-
icapped (coming from state budget), co-payment of patients
(paid out-of-pocket of patients) for subsidized drugs. The statis-
tical analysis was carried out with SPSS version 12.01. Small
areas refer to the postal code (zip code) districts of Hungary and
the patients were assigned to small areas according to their 
permanent address. The Geographical Information system (GIS)
analysis was carried out by the MapInfo Professional software
version 7.5. RESULTS: The health insurance reimbursement of
drugs paid by the National Health Insurance Fund Administra-
tion is signiﬁcantly higher (p < 0.05) in the southern and eastern
part of Hungary. The maximum reimbursement for socially
handicapped paid by the National Health Insurance Fund
Administration is also signiﬁcantly higher (p < 0.05) in the
eastern part of Hungary. The co-payment of patients is signiﬁ-
cantly higher (p < 0.05) in the western and central regions of
Hungary. The results are presented on GIS maps also. CON-
CLUSIONS: The GIS analyses help to identify the geographical
inequalities of the drug expenditures coming from different
sources. In the more developed regions (western and central
regions) the willingness and ability to pay the co-payment is
higher. In the less developed regions of Hungary (northern and
eastern regions) the people more rely on the reimbursement for
socially handicapped ﬁnanced from the state budget.
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OBJECTIVE: To investigate whether patients with a $1,000
annual prescription drug beneﬁt cap reduced their drug con-
sumption prior to exceeding the cap threshold. Previously, we
found that the drug cap reduced overall drug consumption
during the year. METHODS: All 183,640 subjects were 65+
years with Medicare insurance, had tiered copayments ($10 for
generic & $15–35 for brand drugs), and were members of an
integrated, prepaid delivery system: 146,050 subjects had an
annual $1000 drug beneﬁt limit; and 37,590 subjects had no
beneﬁt limit (because of supplementary insurance from former
employers rather than individual choice). To compare drug con-
sumption (measured in dollars) below the cap amount, we exam-
ined the risk of cap and non-cap subjects consuming $250, $500,
$750, and $1000 in 2003 using proportional hazard models for
each of these thresholds. We adjusted for age, gender, race/eth-
nicity, brand copayment amount, prior visits, socioeconomic
status, comorbidity, and having a regular primary care provider.
RESULTS: Among the 183,640 subjects, 16,657 (11%) of sub-
jects with a cap and 7,888 (21%) of subjects without caps
exceeded the $1,000 cap threshold during 2003. After adjust-
ment for covariates, subjects with a cap were signiﬁcantly less
likely to exceed the $1,000 cap threshold (HR = 0.61, 95% CI:
0.56–0.66), compared with subjects without a cap. Similarly,
subjects with a cap were signiﬁcantly less likely to exceed lower
drug consumption thresholds during the year, compared with
